Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(c) On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc.
(the "Company") appointed Brendan P. Teehan as Executive Vice President, Chief
Operating Officer and Head of Commercial and as the Company's principal
operating officer. The Company's press release dated November 1, 2021 is
attached as Exhibit 99.1.
Mr. Teehan, age 53, joined the Company in July 2018 as Vice President, Insights,
Analytics and Commercial Operations. In March 2021, he was promoted to Senior
Vice President, Chief Insights and Analytics Officer. Prior to joining the
Company, Mr. Teehan served as Vice President, Provider Solutions at TESARO,
Inc., a commercial-stage oncology company, from June 2016 to July 2018, and as
Vice President, then Senior Vice President, Pharmacy Services at RainTree
Oncology, an oral oncology services company, from April 2012 to April 2016. Mr.
Teehan earned a Bachelor of Arts in government and international relations from
the University of Notre Dame and an M.B.A. from Carnegie Mellon University,
Tepper School of Business.
There is no arrangement or understanding between Mr. Teehan and any other person
pursuant to which Mr. Teehan was selected as an officer, and there are no actual
or proposed transactions between the Company and Mr. Teehan or any related
person that would require disclosure under Item 404(a) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press Release dated November 1, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses